Pablo Umana

Pablo Umana publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Pablo Umana sits on this spectrum.

Pablo Umana D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Pablo Umana sits on this spectrum.

Best Publications

• Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

  Ekkehard Mössner;Peter Brünker;Samuel Moser;Ursula Püntener

  1314
  Citations

• Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose

  Claudia Ferrara;Sandra Grau;Christiane Jäger;Peter Sondermann

  909
  Citations

• Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

  Unknown

  816
  Citations

• The Carbohydrate at FcγRIIIa Asn-162 AN ELEMENT REQUIRED FOR HIGH AFFINITY BINDING TO NON-FUCOSYLATED IgG GLYCOFORMS

  Unknown

  422
  Citations

• Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

  Christian Klein;Alfred Lammens;Wolfgang Schäfer;Guy Georges

  413
  Citations

• Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions

  Tilman Schlothauer;Sylvia Herter;Claudia Ferrara Koller;Sandra Grau-Richards

  413
  Citations

• Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

  Sylvia Herter;Frank Herting;Olaf Mundigl;Inja Waldhauer

  408
  Citations

• Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors

  Daniela Stefanie Thommen;Jens Schreiner;Philipp Müller;Petra Herzig

  406
  Citations

• Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

  Martin Hutchings;Franck Morschhauser;Gloria Iacoboni;Carmelo Carlo-Stella

  382
  Citations

• PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program

  Unknown

  378
  Citations

• A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.

  Marina Bacac;Tanja Fauti;Johannes Sam;Sara Colombetti

  370
  Citations

• Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy.

  Maud Mayoux;Andreas Roller;Vesna Pulko;Stefano Sammicheli

  369
  Citations

• Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

  Christian Klein;Inja Waldhauer;Valeria G. Nicolini;Anne Freimoser-Grundschober

  334
  Citations

• Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment

  Anja Seckinger;Jose Antonio Delgado;Samuel Moser;Laura Moreno

  324
  Citations

• PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells

  Unknown

  318
  Citations

• Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co‐expression of heterologous β1, 4‐<i>N</i>‐acetylglucosaminyltransferase III and Golgi α‐mannosidase II

  Unknown

  298
  Citations

• Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies.

  Gerhard Niederfellner;Alfred Lammens;Olaf Mundigl;Guy J. Georges

  286
  Citations

• Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

  Christina Claus;Claudia Ferrara;Wei Xu;Johannes Sam

  256
  Citations

• CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.

  Marina Bacac;Sara Colombetti;Sylvia Herter;Johannes Sam

  229
  Citations

• Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity

  Sylvia Herter;Martina C. Birk;Christian Klein;Christian Gerdes

  174
  Citations